Dr. Sandor Demeter
Exciting New Cancer Therapy
The Canadian Agency for Drugs and Technologies in Health Care (CADTH), via the Pan Canadian Oncology Drug Review process, has recently recommended Lu 177 Dotatate for the treatment of a subset of rare neuroendocrine tumors where the tumors are not resectable. The drug, which is linked to a radioactive isotope, is injected and localizes to the cancer tumors resulting in targeted radiotherapy.
We currently send patients out of the Province for treatment but we have the skills and expertise within Cancer Care MB and Shared Health to treat these patients in MB.
It will be great for patients, and their family and friends, when we can offer this service at home.
Photo - urban art on McDermot Avenue by Princess Street
Pan Canadian Oncology Drug Review